Company: CERO
Filing Date: 2025-01-14
Form Type: 424B3
Source: 0001213900-25-003436
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-14
Form: 424B3
Chunk 4
---
 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on which registered |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market                      |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.02 Unregistered Sales of Equity Securities

On January 6, 2025, a holder
of warrants (“Preferred Warrants”) to purchase shares of Series A Preferred Stock, par value $0.0001 per share (“Series
A Preferred Stock”) of CERo Therapeutics Holdings, Inc. (the “Company”), exercised 625 Preferred Warrants for shares
of Series A Preferred Stock with an aggregate stated value of $625,000, at an exercise price of $800 per share (the “Warrant Exercises”),
reflecting the 20% original issue discount applicable to the issuance of shares of Series A Preferred Stock relative to the stated value
thereof. The Company received $500,000 of cash proceeds from the Warrant Exercises. Such holder converted the shares of Series A Preferred
Stock into an aggregate of 16,385,275 shares of common stock, par value $0.0001 per share (“Common Stock”) of the Company.
The receipt of such proceeds was included in the cash balance of the Company as of January 7, 2025 previously reported on a Current Report
on Form 8-K. In connection therewith, on January 6, 2025, the Company issued warrants to purchase an aggregate of 16,385,275 shares of
Common Stock, with an exercise price of $0.0582 per share,